Low Li Sian, Scholtz David, Leyland John, Nair Shiva Madhwan
Urology Department, Level B1, Waikato Hospital, Hamilton, New Zealand.
Urol Case Rep. 2021 Feb 3;36:101592. doi: 10.1016/j.eucr.2021.101592. eCollection 2021 May.
The use of intravesical BCG has improved the survival and outcomes in the treatment of bladder cancer. However, the worldwide shortage of OncoTice BCG has caused disruption and changes in treatment regimes, leading to use of alternative strains. We describe a severe complication as the result of using intravesical SII Onco BCG for the treatment bladder cancer, in an 82 year old man presenting with granulomatous epididymo-orchitis.
膀胱内灌注卡介苗(BCG)的应用改善了膀胱癌治疗的生存率和预后。然而,全球范围内OncoTice BCG的短缺导致了治疗方案的中断和改变,进而促使人们使用替代菌株。我们描述了一名82岁男性因膀胱内灌注SII Onco BCG治疗膀胱癌而出现严重并发症,表现为肉芽肿性附睾睾丸炎。